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Abstract Public funding for research on the action of drugs in countries like the United States
requires that racial classification of research subjects should be considered when defining the com-
position of the samples as well as in data analysis, sometimes resulting in interpretations that Whites
and Blacks differ in their pharmacogenetic profiles. In Brazil, pharmacogenomic results have led to
very different interpretations when compared with those obtained in the United States. This is
explained as deriving from the genomic heterogeneity of the Brazilian population. This article argues
that in the evolving field of pharmacogenomics research in Brazil there is simultaneously both an
incorporation and rejection of the US informed race-genes paradigm. We suggest that this must be
understood in relation to continuities with national and transnational history of genetic research in
Brazil, a differently situated politics of Brazilian public health and the ongoing valorization of mis-
cegenation or race mixture by Brazilian geneticists as a resource for transnational genetic research.
Our data derive from anthropological investigation conducted in INCA (Brazilian National Cancer
Institute), in Rio de Janeiro, with a focus on the drug warfarin. The criticism of Brazilian scientists
regarding the uses of racial categorization includes a revision of mathematical algorithms for drug
dosage widely used in clinical procedures around the world. Our analysis reveals how the incor-
poration of ideas of racial purity and admixture, as it relates to the efficacy of drugs, touches on
issues related to the possibility of application of pharmaceutical technologies on a global scale.
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Introduction
In the same way that they access their bank accounts and e-mail, physicians and other health
professionals in any part of the world can download to their computers, tablets or cell phones a
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program that calculates the dosage of warfarin anticoagulant to administer to their patients.
Since the 1950s warfarin has been the anticoagulant most used worldwide and it is routinely used
whenever patients require medical treatment that involves an anticoagulant. One of the most
widely used algorithms is available on the website www.warfarindosing.org, from Washington
University at St. Louis, USA, which had been visited more than 580 000 times as of April 2014.
The algorithm was developed by “international collaborations of biostatisticians, geneticists,
pharmacists, and physicians who share anonymous data to improve warfarin dosing”.
Even those who do not routinely treat hospital patients can easily use the site. A click on the
option “warfarin dosing” opens a page entitled “Required patient information”. The page has a
number of spaces to be filled in with information, including the patient’s age, sex, weight, height,
whether a smoker, as well as previous clinical history, other medications taken and seven genetic
characteristics. Of particular relevance to the topic of this article are two specific questions,
one regarding the “ethnicity” of the patient (with the options “non-Hispanic”, “Hispanic” and
“unknown”) and the other regarding “race” (with the options “African American or Black”,
“American Indian or Alaska Native”, “Asian or Indian Subcontinent”, “Native Hawaiian or
other Pacific Islander”, “White, Caucasian, or Middle Eastern” and “Other”).
Pharmacogenetics is a branch of medical science specializing in the study of how genetic
characteristics affect responses to medications. A fundamental premise of pharmacogenetics is
that the efficacy and safety of the use of a drug to treat patients may vary, depending on the
genetic profile of the individuals and of populations. Two important pioneers in the field have
been the North American ArnoMotulsky (see Motulsky, 1964; Gurwitz andMotulsky, 2007)
and the German–Canadian doctor Werner Kalow (Jones, 2013). In 1962, Kalow published a
book entitled Pharmacogenetics: Heredity and Response to Drugs that has become an
important point of reference for researchers in this area (Kalow, 1962). More recently, Kalow,
with other researchers, published Pharmacogenomics, Second Expanded Edition that updated
and amplified the previous work (see Kalow et al, 2005). While the new book maintained a
focus on genes (or polymorphisms) that determine differences in the metabolism of certain
drugs, it added an approach based on DNA. As a consequence, pharmacogenetics also came
to be called pharmacogenomics (see Suarez-Kurtz, 2010).
In a provocative analysis, the anthropologist Fullwiley (2007) challenges what she calls
“institutionalizing race at the molecular level” in the research practices of pharmacogenomics
in the United States. She argues that with the increasing emphasis on the application of
biomedical technology at the level of the individual (“individualized medicine”), as in the case
of pharmacogenomics, a revival of racialized approaches has occurred. The algorithm to
calculate the dosage of warfarin may be taken as an example of this “reinscription of race” to
which Fullwiley refers. The irony of this development has not been lost to anthropologists and
science, technology and society (STS) scholars, since it was from genetics, especially in the second
half of the twentieth century, that a powerful denial of the biological concept of race emerged.
Scholars like Fullwiley (2007), Bliss (2011, 2012), Lee (2005, 2012) and Montoya (2007, 2011)
argue that the “molecularizing of race” in pharmacogenomics in the United States is a dynamic
concept with multiple and complex aspects. This not only determines how scientists look at
biological differences between human populations in socio-cultural terms, but may have many
further effects including, among others, how inequalities in health are related to ethnic/racial
categories, and how agencies that regulate and finance research are influenced to include
questions relating to race. Lee refers to the broader institutional context in which these
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developments are taking place in the United States in terms of an “infrastructure for racializa-
tion”. She sees these developments in terms of a growing alignment between “research on human
genetic variation that maps genes to social categories of race[…] the pervasive use of race as a
proxy for risk in clinical medicine, and the search for new ‘racially inscribed’ market niches by
the pharmaceutical industry” (Lee, 2005, p. 2133).
The criticisms voiced by Fullwiley, Bliss, Montoya and Lee are part of broader views about
the perspective on race that has emerged in the context of new genetic technologies (see Rose,
2007; Koenig et al, 2008; Whitmarsh and Jones, 2010; Kahn, 2013). Recent analyses have
discussed both the ‘promise’ and the ‘dangers’ involved in the revival of the idea of race, as
well as the ways it has been applied in fields related to health regulation, knowledge and care.
As the editors of the book Revisiting Race in a Genomic Age commented, “contrary to
expectation and hopes, post-genomic science has revived the notion of racial category as an
indicator of biological difference” (Koenig et al, 2008, p. xx). The revived notion of race and
the controversies that surround it exemplify how old and recent categories, practices and
institutions have acquired new emphases and significance in the context of the emergence of
the new genetic technologies, including pharmacogenomics.
Exemplified by the authors cited above, most criticism of the racialization of biomedical
technologies and practices comes from the social sciences, especially anthropology and
sociology, as well as the field of STS.1 In Brazil, in what can be regarded as an internal
national critique (that nevertheless aims to inform global research agendas), influential
researchers in the field of pharmacogenomics have questioned the use of ethno/racial
categories as measures of biological variability. For example, Guilherme Suarez-Kurtz, a
prominent investigator in the field of pharmacogenetics, coordinator of the National Network
of Pharmacogenetics and Pharmacogenomics, senior member of the Brazilian Academy of
Sciences, and researcher at the Instituto Nacional do Cancer (INCA or National Cancer
Institute) in Rio de Janeiro, commented recently on the application of algorithms to estimate
warfarin dosage to research on Brazilian populations.
… warfarin dosing algorithms that have a ‘race’ term defined by criteria prevalent in a
given region or country (e.g., the United States OMB) are unlikely to be applicable
worldwide, especially in extensively admixed populations, such as Brazilians. On a
broader perspective, one may ask whether the global population diversity may be
captured by inserting ‘race’ terms in PGx algorithms that are sufficiently ‘friendly’ to be
adopted by the practicing prescriber?
(Suarez-Kurtz, 2010, pp. 3–4).
Authors such as Suarez-Kurtz and the geneticist Sergio Pena have emphasized the mixed race
question in Latin America, and especially in Brazil, at the same time criticizing the racial
perspective in pharmacogenomics (referred to by the euphemism ‘population-based drug
development and prescription’) (see Suarez-Kurtz and Pena 2006a, b; Suarez-Kurtz, 2010;
Pena, 2011; Pena et al, 2011). They link the production of knowledge in pharmacogenomics to
such a broad question as inequalities in public health policy, although these moral claims,
somewhat differently to the United States, rest on the need to demolecularize race and genomics
as the rest of the article examines. Looking at Latin America, especially with regard to race
1 For exceptions, see Caulfield et al (2009) and Urban (2010).
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mixing, these scientists argue that the region may provide a counterpoint (because of its high level
of ‘genetic admixture’) to thinking of pharmacogenomics in terms of the world as a whole.
The aim of this article is to discuss issues that have been the subject of recent debates in the
field of pharmacogenomics, especially those concerning the use of race/color categories, with
resulting effects on the genomic profile of human populations. On the basis of a Brazilian case,
we will examine how pharmaceutical technologies, generally developed in North America or
Europe, and their prescribed uses (as in the case of ethno-racial categories) circulate globally.
In the first place, we situate pharmacogenomic research in Brazil in the context of continuities
in the historical studies on the genomic diversity of Brazilian populations, which notably
increased in the 1990s and the early 2000s. Then we argue that a central point of
pharmacogenomic research in Brazil has been to emphasize the specific historical trajectory
of the country that led to extensive racial mixing and the resulting impact on issues as diverse
as the use of algorithms for the administration of drugs, the use of color/race or ethnic
categories in genomic research, and the directions of public policy in the area of health.
The second theme, deployed as a case study, will be the exploration of research on the
anticoagulant warfarin by Brazilian pharmacologists and geneticist. We then situate the
criticism of the focus on race that has emerged from pharmacogenomic research in Brazil in
relation to the broader debates in the anthropology of science literature on genomics research
on pharmacogenomics as well as studies of admixture. We see parallels and differences in the
way that these debates have been critiqued and theorized with the Brazil context, where there
is both what might be seen as incorporation and simultaneous rejection of transnational
genomic research that makes use in different ways of race and color categories.
Biological Diversity of the Brazilian Population
In order to understand recent discussions about race/color categories in the context of research
in pharmacogenomics in Brazil, it is essential to be aware of their background, that is, the
scientific work on the biological diversity of the Brazilian population that has been done over
the last decade. A number of the works by Suarez-Kurtz on pharmacogenomics refer to this
literature, especially to the research by the geneticist Sergio Pena since 2000. As we will see
in this section, genomic interpretations of the biological make-up of Brazilians relate to
perspectives that go back half a century to the origin of human population genetics in Brazil.
In Brazil, human population genetics became established as a specific field of investigation in
the 1950s, when research groups were formed in several Brazilian institutions. The support of
the Rockefeller Foundation was crucial, since, among other initiatives, it funded a number of
trips to Brazil in the 1940s and 1950s by the geneticist Theodosius Dobzhansky of Columbia
University (Glick, 1994; Santos andMaio, 2004; Souza et al, 2013; Souza and Santos, 2014). In
partnership with the Biology Department of São Paulo University (Universidade de São Paulo –
USP), and especially with the Brazilian scientist André Dreyfus, Dobzhansky carried out field
studies in various parts of the country, gave courses and took part in training young Brazilian
geneticists. Many of them would go on to write their doctoral dissertations on Drosophila
genetics. In the 1950s, some of these geneticists turned to the emerging field of human
population genetics. Also with the support of the Rockefeller Foundation, investi-
gators who would become important figures in Brazilian genetics, such as Francisco Salzano,
Newton Freire-Maia and Pedro Saldanha, went to the United States for postdoctoral training,
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especially at the Department of Human Genetics of the University of Michigan, with James
Neel. Moreover, in the early 1960s a group of Brazilian geneticists earned their doctorates at the
University of Hawaii with the population geneticist NewtonMorton (Souza and Santos, 2014).
This first generation of researchers in human genetics formed in the 1950s and 1960s mainly
followed two lines of research (Souza et al, 2013; Souza and Santos, 2014). One was the
genetics of indigenous populations, in which the work of Francisco Salzano, in partnership
with James Neel, stands out (see Santos, 2002; Lindee, 2004; Souza and Santos, 2014;
Santos et al, 2014b). Their interest centered on genetic evidence about the peopling of the
Americas, and study of the processes that produce human biological diversity (so-called
micro evolutionary processes). A second line that was prominent at the beginning of human
population genetics in Brazil, and is of particular interest for this study, concentrated on
understanding, from the viewpoint of genetics, how the Brazilian population was formed from
the interaction of the so-called main ‘racial stocks’ (that is, European, African and
Amerindian) (see Salzano and Freire-Maia, 1970).
On this second line, through analysis of the frequency and distribution of alleles of the
classic genetic markers (the ABO blood groups, Rh, Diego factor and serum proteins, as well
as gamma globulins), interest largely focused on the investigation of “racial admixture” (Souza
et al, 2013; Souza and Santos, 2014; Santos et al, 2014a). Influenced by the neo-Darwinian
perspective that increasingly dominated human population studies, and, at the same time,
infused with racialized views, these studies were largely aimed at analyzing processes of genetic
flow between the ‘parental populations’. The principal geneticists who developed studies of
‘racial admixture’ in the 1950s and 1960s, such as Pedro Saldanha, Newton Freire-Maia,
Ademar Freire-Maia, Eliane Azevedo, Henrique Krieger and Francisco Salzano, believed that
Brazil presented particularly propitious conditions for genetic studies, in view of the genetic
diversity, the social, demographic and epidemiological conditions of the country. Like other
regions where there was intense immigration and racial mixing, such as Hawaii (Anderson,
2012), Brazil was seen as a great “racial laboratory”, as the Brazilian geneticist Newton Freire-
Maia entitled one of his books (Brasil: Laboratório Racial; Brazil: Racial Laboratory),
published in 1973. In the opinion of Salzano and Freire-Maia, as they wrote in a book
published in 1970, Brazilian populations “present the geneticist and anthropologist an excellent
opportunity for the study of complex and fascinating problems”, in view of “the extreme variety
of their original ethnic groups, the widespread miscegenation, and their distribution in all kinds
of environmental conditions” (Salzano and Freire-Maia, 1970, p. xv).
Genetic research on human populations went through a fundamental methodological
transition during the 1980s, when the classic genetic markers were increasingly replaced
by DNA markers. What happened in Brazil was that the two agendas described above,
which already dominated research in the genetics of human populations (that is, genetics of
indigenous populations and studies of the biological diversity of the Brazilian population)
were methodologically updated in the form of genomics. The same themes continued to be
central to the research agenda of human genetics in Brazil.
In the early 2000s, the publication of two articles that used a genomic approach
may be considered a watershed in the investigation of human biological diversity in Brazil
(Alves-Silva et al, 2000; Carvalho-Silva et al, 2001). These publications, which were based
on analysis of mitochondrial DNA markers and the Y chromosome, were by a group
coordinated by the geneticist Sérgio Danilo Pena, of the Federal University of Minas Gerais
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(Universidade Federal de Minas Gerais). The researchers obtained from paternity testing
clinics genetic samples of approximately 250 men self-classified as ‘White’ who came from
different regions of the country. Analyzing polymorphisms of the Y chromosome in these
samples showed that a vast majority of markers could be identified as European in origin, with
a very low frequency of markers originating in sub-Saharan Africa, and no Amerindian
genetic contribution. On the other hand, the analyses of mitochondrial DNA gave a much
more complex picture, with 33 per cent Amerindian genetic contribution and 28 per cent
African contribution, a surprisingly high African and Amerindian percentage in the matrilines
of the White men studied. As the authors noted in a popular science article, this pattern of
differential reproduction (with patrilineages verified through the Y chromosome predomi-
nantly of European origin, and matrilineages verified through mitochondrial DNA as largely
African and Amerindian) made much sense in view of the history of the colonization of
Brazilian territory from the sixteenth century: “the first Portuguese immigrants did not bring
their wives, and historical records indicate that they rapidly began a process of miscegenation
with indigenous women. With the arrival of slaves, beginning in the second half of the
sixteenth century, the miscegenation was extended to African women” (Pena et al, 2000,
p. 25). In the geneticists’ perspective, this research demonstrates how genetically mixed is the
sample of (self-classified) White men, since the majority of the matrilineages studied
(approximately 60 per cent) had an Amerindian or African origin.
As well as research using mtDNA and the Y chromosome, Pena’s group, early in the 2000s,
carried out investigations based on autosomal markers, that is, genetic traits located in the cell
nucleus (Parra et al, 2003). In a study entitled “Color and genomic ancestry in Brazilians”
a group of approximately 170 people from Queixadinha, a community in the interior of
Minas Gerais, in the southeast region of the country, was investigated. Possibly the principal
finding of this study was that there was no correspondence between the morphological and
the biological classification of this sample. The researchers noted that a large overlap made it
difficult to distinguish the genomic characteristics of persons morphologically classified as
‘White’, ‘Brown’ or ‘Black’. In contrast, a comparison of the genetic characteristics of three
other groups (Africans of São Tomé, Amazonian indigenous populations and Portuguese)
showed correspondence between their morphological and genetic characteristics. The authors
concluded: “Our data suggest that in Brazil, at an individual level, color, as determined by
physical evaluation, is a poor predictor of genomic African ancestry, estimated by molecular
markers” (Parra et al, 2003, p. 177). A study along similar lines carried out by the Pena group
a few years later with samples from the city of São Paulo reached a similar conclusion: “These
results corroborate and validate our previous conclusions using ancestry-informative markers
that in Brazil at the individual level there is significant dissociation of color and genomic
ancestry” (Pimenta et al, 2006, p. 190).
Following the example of the group from the Federal University of Minas Gerais,
coordinated by Pena, since the early 2000s there has been intense production of studies on
the genomic diversity of the Brazilian population by research groups from various other
Brazilian institutions. For example, there are groups affiliated with the Federal University of
Rio Grande do Sul, the University of São Paulo, the Federal University of Paraná, the Catholic
University of Brasília and the Federal University of Pará, among others (see Santos et al,
2014a). The investigations by these research groups located in different parts of the country,
from north to south, and based on samples collected in their respective regions, have resulted
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in intense interest in understanding not only the general aspects (on a national scale) but also
how local/regional dynamics have been involved in the make-up of Brazilian populations.
We can cite as an example, the studies of the research group from the Federal University of
Rio Grande do Sul on the formation of the so-called ‘Gaúcho’ population (that is, from the
state of Rio Grande do Sul) (see Kent and Santos, 2014). The interpretive models of Pena and
his collaborators tend to focus on the nation as a whole, so at times analyses based on
populations that are more socially and geographically bounded have resulted in discrepant
interpretations. In the case of Rio Grande do Sul, Guerreiro-Junior et al (2009, p. 1) indicated
that their findings “emphasize the need to consider in Brazil, despite some general trends, a
notable heterogeneity in the pattern of admixture dynamics within and between populations/
groups”. Zembrzuski et al (2006), by their turn, argue that in Rio Grande do Sul, a state that
has been the scene of intense European colonization, and where there is less miscegenation
than in other parts of the country, there is, indeed, a close association between genomic profile
and physical appearance.
In spite of different interpretations of certain aspects of the biological diversity of the
Brazilian population, scientific studies done by the various research groups tend to agree that
in Brazil there is great genetic heterogeneity at both the national and regional levels.2
Moreover, this diversity has been interpreted by the geneticists as derived from the interaction
among populations of European, African and Amerindian origin that, depending on the
region of the country, each with its own particular history, resulted in genomic profiles with
particular characteristics. Therefore we can affirm that in the studies on biological diversity in
this genomic era there is marked continuity with perspectives that predominated at the origins
of population genetics in the country in the 1950s and 1960s. We see in both eras an effort to
emphasize genetic diversity of the population in terms of national difference and the
uniqueness of the South American region. At the same time there is also marked continuity
in the effort to highlight the transnational utility of Brazil as a ‘racial laboratory’ for genetic
research (Salzano and Freire-Maia, 1970; Freire-Maia, 1973; Santos et al, 2014a, b; Souza
and Santos, 2014), while also continuing to make use of what are assumed to stable parental
population categories referenced through the notion of tri-hybrid ancestries.
Starting approximately in 2005, studies on the genetic profile of the Brazilian population
became increasingly made part of investigations in the field of pharmacogenomics. This is
evident in the work of Suarez-Kurtz and Pena, published in 2006, entitled, “Pharmacoge-
nomics in the Americas: Impact of genetic admixture”. In this work they affirm:
Because interethnic admixture is either common or increasing at a fast pace in many, if
not most populations, extrapolation on a global scale of pharmacogenomic data from
well-defined ethnic groups is plagued with uncertainty. Intra-ethnic diversity adds
complexity to the scientific appraisal, regulatory decisions and, eventually, prescribing
of drugs purportedly targeted to a given ‘race’ or ethnicity. Pharmacogenetics/genomics
has the potential to benefit people worldwide and to reduce the health disparities
between developing and developed nations. This goal is unlikely to be achieved by
relinquishing the notion of personalized drug therapy tailored to individual genetic
2 See Kent and Santos (2014), Maio and Santos (2010), Santos and Maio (2005) and Santos et al (2009,
2014a) for critical analyses on the incorporation of arguments derived from human population genomic
research into the debate on race and affirmative action in Brazil.
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characteristics – the original promise of pharmacogenetics – in favor of a model
(pharmacogenomic?) of population-based drug development and prescription, with all
its potential pitfalls, especially when extended to admixed populations in developing or
developed nations.
(Suarez-Kurtz and Pena, 2006a)
In recent years, Suarez-Kurz and Pena have carried out joint studies (Suarez-Kurtz et al, 2007,
2010a, b; Pena et al, 2011; Sortica et al, 2012), some of which we will comment on later in this
work. What we should like to stress here is the focus on a model of genetic diversity that
emphasizes the topic of admixture and how this is something to be considered not only in the
conduct of research, but also in plans to apply knowledge derived from pharmacogenomics to
public policy. Quoting Pena (2007), Suarez-Kurtz (2010) speaks of the existence of three
models for the evolution and structure of genetic diversity in the human species. The first,
referred to as typological, that prevailed in the nineteenth and the beginning of the twentieth
century, divided the human species into ‘races’ conceived as different from one another and
internally homogeneous; the second, called ‘population’, that prevailed from the middle of the
twentieth century, is a product of the Neo-Darwinian syntheses of the first decades of the
century. According to Suarez-Kurtz (2010), “both models are poor descriptors of admixed
populations, since genetic admixture is best modeled as a continuous variable” (p. 1).
In this sense, the model the pharmacologist considers the most adequate to describe
the biological variability of the human species, and therefore that most appropriate for
use in pharmacogenomic studies, is the ‘individual singularity’ model. Quoting Patrinos
(2004), Suarez-Kurtz (2010, p. 1) argued that “each person must be treated as an individual…
rather than as an exemplar of a race”. Yet while this is a model of individuality that, in Brazil
and elsewhere, is informed by the promissory dimensions of pharmacogenetic research as
‘personal medicine’, it also stands in contrast to Fulwilley’s critique of personalized pharmaco-
genomics in the United States in which admixture is read through histories of hypodescent and
biracial hybrids (Fullwiley, 2007). In Brazil such a model, in the context of pharmacogenomics
research, is instead situated and emerges from complex clinal understandings of inherent
individual genetic ancestral variability and mixture that is linked in Brazil to quite to different
histories and politics of race, color and national identity (see for instance, Maio and Santos,
2010; Gibbon et al, 2011; Souza and Santos, 2014; Santos et al, 2014a, b).
As we shall see in the next section, the pharmacogenomic research that Suarez-Kurtz is carrying
out on warfarin has been strongly influenced by this perspective of ‘individual singularity’ and
thus is distanced from algorithms that define dosage based on the notion of ‘race’.
Warfarin and Miscegenation
Suarez-Kurtz, who has been affiliated since 1960 with the Federal University of Rio de Janeiro
(Universidade Federal do Rio de Janeiro, or UFRJ), has dedicated his working life to
the fields of physiology and pharmacology. From the start of his career he traveled extensively
abroad for study and research. He would continue the research that he developed at institutions
in France, England and the United States when he returned to Brazil, sometimes adapting it to
local conditions. In the 1970s and 1980s, he continued in Brazil the studies of muscular
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physiology, using crayfish as the experimental model, that he had begun abroad, substituting a
small blue crab that scuttles along Brazilian beaches. Studies on frogs, funded by the American
Association for Muscular Dystrophy, were continued in the UFRJ laboratories with mice and
opossums. In his search to unite creativity (expressed by designing novel experiments) with
continuity (by re-adapting the experiments begun abroad to local conditions), he developed an
approach that incorporated autochthonous objects as essential elements in universal models. In
one of the interviews he gave us,3 Suarez-Kurtz defined his search for a “strategic advantage” as,
for him, an alternative to what might be considered by Brazilian scientists mere repetition of
what was already done abroad.
In the early 2000s, when Suarez-Kurtz began research in pharmacogenetics at the
National Cancer Institute (INCA) in Rio de Janeiro, he used this creative/adaptive
approach in new circumstances. He made the Brazilian population the object of his
research in pharmacogenomics, but Suarez-Kurtz chose not to accept its distinctive
character as a variation on a general paradigm, but rather to question the viability of a
model accepted by pharmacogenetics as universal. It was the perception of the uniqueness
of the autochthonous object as something innovative and indispensable for the develop-
ment of pharmacogenetics that led him to affirm that this was no longer a ‘strategic’ choice
for discussion, but a specific with global relevance. This approach that characterizes the
research on pharmacogenomics of warfarin carried out at INCA reflects strategies that
have long been embedded in genetic research in Brazil, as we have already discussed, with
their focus on both aligning with transnational research agendas and establishing Brazil as
uniquely different and important context for study (Maio and Santos, 2010; Gibbon et al,
2011; Souza and Santos, 2014; Santos et al, 2014a, b).
Warfarin, which has been in use since the 1950s, combines, according to Suarez-Kurtz,
various characteristics that make it an interesting model for study: (i) it is the most commonly
prescribed oral anticoagulant in Brazil and worldwide, (ii) there is large inter-individual
variation in the required dosage, (iii) its therapeutic index is narrow and incorrect
dosage, especially during the initial phase of treatment, carries a high risk of bleeding or failure
to prevent thromboembolism, and (iv) a reliable biomarker, the international normalized ratio,
is available for quantifying warfarin’s anticoagulant effect (Perini et al, 2008, p. 726;
Suarez-Kurtz, 2010, p. 6). Moreover, from the viewpoint of genetics, its inheritance is relatively
simple, as polymorphisms in two genes (CYP2C9 and (VKORCI) have been identified as
associated with the clinical response to warfarin (Suarez-Kurtz, 2010, p. 6).
In the article entitled “Pharmacogenetics of warfarin: development of a dosing algorithm for
Brazilian patients”, Perini et al (2008) investigated the predictive capacity of an algorithm
for dosing warfarin, comparing a total of 390 patients self-classified as ‘White’, ‘Intermediate’
or ‘Black’, from a cardiology hospital in Rio de Janeiro4. The analyses indicated a wide
3 Interviews with Suarez-Kurtz were carried out by Silva and Santos on 25 November 2010 and 5 April 2011
in his office at the National Cancer Institute (INCA) in Rio de Janeiro. The interviews were recorded and
later transcribed for analysis.
4 In our interviews, Suarez-Kurtz affirmed that in the first research he did on the interface of race and
pharmacogenomics was the one whose results were reported in Reis et al (2003). He referred critically to this
study, because at the time he used the expressions “Afro-derived” and “Euro-derived” and “having
interethnic admixture” that he ceased to use in favor of a focus more aligned with Pena’s theoretical
approach.
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variation in warfarin dosage according to color/race groups (from 5 to 75mg/week), with
differences between ‘White’ (lower dose) on one hand, and ‘Black’ and ‘Intermediate’ on the
other (Perini et al, 2008, p. 722). Results showed that patients of the three color/race groups
varied in allelic frequencies and in the distribution of genotypes of the two polymorphisms,
and that the genotypes were associated with the dose of warfarin, although with wide overlap
in the required dose (p. 724). The authors also estimated what would be the most appropriate
algorithm to predict the warfarin dose for this group of patients. While in the univariate
analysis they observed that the color/race variable was statistically significant, in the
multivariate regression analysis this variable was not retained. As to the relationship between
the predicted dose and the required dose, Perini et al (2008, p. 725) argued that there was
overlap among the color/race groups. The authors also emphasized that, from a statistical
point of view, the algorithm that does not include the color/race variable shows better results
when compared with others developed in other parts of the world. In comparison with an
algorithm developed in the United States they commented:
… self-reported race/color was not a significant predictor of warfarin requirements in
our patient cohort, despite the significant differences in the maintenance warfarin dose
across the race/color groups. This contrasts with a recently published warfarin dosing
algorithm derived from a large cohort of US patients that included ‘African-American
race’ as a significant covariate. This discordance may be related to a number of factors
including (i) our observation that VKORC1 and CYP2C9 genotype differences in
warfarin dose requirements exist independent of self-reported race/color among
Brazilians …, (ii) the greater proportion of European genetic ancestry among black
Brazilians compared with African Americans, and (iii) the poor correlation of self-
reported race/color with genetic ancestry among Brazilians
(Perini et al, 2008, p. 726).
In Brazil, Perini et al (2008) concluded, the most appropriate option would be to consider the
individual portion of African genomic ancestry, independent of color/race self-classification.
According to them, “… because of the heterogeneity and extensive admixture of the present-
day Brazilian population, extrapolation of data derived from well-defined ethnic groups is
clearly not applicable to the majority of Brazilians” (p. 722).
The work of Perini et al (2008) did not include information on the genetic profile of the
individuals analyzed. The next step in the research coordinated by Suarez-Kurtz was to take
into consideration genomic profiles, using for this purpose samples collected through the
National Network of Pharmacogenetics and Pharmacogenomics (REFARGEN), created in
2003 by the initiative of Suarez-Kurtz himself. This database includes 1037 Brazilians
considered healthy recruited in four regions of the country. As well as being self-classified
by color/race (as ‘White’, ‘Brown’ or ‘Black’) the genomic ancestry of these individuals,
reported in Suarez-Kurtz et al (2007), was evaluated using a panel of 40 genomic markers
(in this case INDELS, or Insertion-Deletion polymorphisms) developed by Sergio Pena’s
team (Bastos-Rodrigues et al, 2006). It is important to note that this panel of genomic
markers is based on 40 INDELS validated in samples from the HGPD–CEPH Human
Genome Diversity Cell Line Panel (see Bastos-Rodrigues et al, 2006). In that publication the
authors write that the methodology “confirmed the partition of worldwide diversity into
five genetic clusters that correspond to major geographical regions” (p. 658), that is, Africa,
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Europe, America, Oceania, Middle East, East Asia and Central/ South Asia. In this sense,
the use of this panel of markers by the Brazilian pharmacogenomic research might be
seen to non-geneticists as contributing to the assumption that there are stable continental
ancestry groups.5
According to Suarez-Kurtz (2010, pp. 2–3), the principal genomic aspects identified in the
REFARGEN samples were the following: (i) most individuals have significant degrees of
European and African ancestry, whereas a sizable number display also Amerindian ancestry;
(ii) the average proportions of European ancestry decreased progressively from ‘White’ (0.86),
to ‘Brown’ (0.68) and then to ‘Black’ individuals (0.43), whereas the opposite trend was
observed with respect to African ancestry; (iii) Amerindian ancestry was relatively constant
across the three groups, ranging from 0.07 and 0.09. On the basis of this characterization,
it was argued that, in the Brazilian case, European and African ancestries have greater
impact on the frequency of polymorphisms of pharmacogenomic relevance, as compared with
Amerindian ancestry. While making use then of genomic markers that could be argued
to reproduce stable categories of ancestry, population or even race, we find Brazilian
pharmacogenomics incorporating the category of ‘Brown’ into their genomic findings and
most importantly explicitly emphasizing the clinal nature of genetic ancestry. That is as
Suarez-Kurtz stated that “the individual proportions of European and African ancestry vary
over wide ranges as a continuum across the Color categories of the Brazilian Census” (Suarez-
Kurtz, 2010, p. 3).
Using the REFARGEN samples, Suarez-Kurtz et al (2010a, p. 1258) carried out an
investigation with the objective of evaluating the effect of three variables (geographic origin,
self-reported color/race and genetic ancestry) on the distribution of four VKORC1 single
nucleotide polymorphisms and their haplotypes in the Brazilian population. They also attempted
to compare the results from the Brazilian samples with collections from Europe and Africa
(specifically Portugal, Angola and Mozambique), with the intent to “explore the genetic
variability of a major pharmacogenomic target in the population of Brazil, having as reference
two of its most important ancestral roots” (ibid.). The main conclusion was the following:
The evidence presented here extends to a major pharmacogenomic target, VKORC1,
the notion that the diversity and heterogeneity of the Brazilian population is not
captured by self-identified race/Color classes. The pattern of distribution of VKORC1
polymorphisms among Brazilians is best described as a continuum, reflecting the
individual proportions of European and African ancestry
(ibid., p. 1265).
In the authors’ opinion, care should be taken when extrapolating pharmacogenomic infor-
mation derived from ‘other ‘racial/ethnic/continental’ groups’ to the Brazilian context.
5 Although the interplay between genes, geography and human variability patterns might not be regarded as a
racialized approach by human geneticists, it tends to be associated with ‘race’ in the eyes of the non-experts.
Concerning the uses of genetic ancestry informative markers, geneticists often argue that they comprise just
a tiny, often non-codifying, portion of the human genome, thus not providing support to a perspective of
race that emphasizes deep and consistent biological differences across racial groups. Notwithstanding, there
are instances, as in the case of companies that market genetic ancestry tests, often aimed at specific ethnic
minority groups such as the African-American, that end up propagating notions that associate genetics with
racial belonging (Bolnick et al, 2007; Bolnick, 2008; Sommer, 2010).
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They question the clinical use in Brazil of algorithms for warfarin dosage that do not take into
consideration the biological diversity of the Brazilian population.6
Going beyond strictly scientific articles, both Suarez-Kurtz and Sergio Pena have published
opinion pieces directed at the general public. In these articles, they stressed how, in their
interpretation, pharmacogenomics and the genetic diversity of the Brazilian population relate
to public health policy. In 2009, Suarez-Kurtz published an editorial in Cadernos de Saúde
Pública/Reports in Public Health, one of the leading journals in public health in Latin America
that is affiliated with an institution (Oswaldo Cruz Foundation, or Fundação Oswaldo Cruz)
of the Ministry of Health. This journal is one of the main Brazilian periodicals that carry
academic papers referring to the National Public Health System (SUS or Sistema Único de
Saúde). In Brazil, this system includes all areas of health, from outpatient care to organ
transplants, with the intent of providing complete, universal and free care for the whole
population of the country. In this editorial Suarez-Kurtz (2009) wrote:
The results [of our research] showed that the heterogeneity of our population must be dealt
with as a continuous variable, which cannot be adequately represented by arbitrary ‘race/
color’ categories. In a PGx-informed context, this implies that each person must be treated
as an individual rather than as an ‘exemplar of a race’, and that the notion of
‘race-targeted’ drugs is unacceptable, especially in the case of admixed populations
(p. 1650).
The results of the research in pharmacogenomics by the INCA might be seen as reflecting the
medication policy of the National Health System, which is carried out by the “National Policy for
Pharmaceutical Assistance”. This policy was declared by the National Health Council in 2004,
and it is an integral part of the “National Health Policy”. One of the purposes of the “National
Policy for Pharmaceutical Assistance” is the “implementation throughout government sectors,
and especially through theMinistry for Science and Technology, of public policy for scientific and
technological development, involving research centers and universities, with the objective of
promoting technological innovation [in the area of medication] that serves the national interest
and the necessities and priorities of SUS” (CNS (Conselho Nacional de Saúde), 2004). Therefore,
there are close links between pharmacogenomic research and the wider area of public health
policy in Brazil. There are though key difference here compared with the United States where
moral claims around public health and genomic research has focused on the rights and needs of
‘underserved’ racialized groups and questions of social justice (Lee, 2005) as we discuss below. In
Brazil, the current SUS priority of health care access for all means that the inequities at stake in
Brazil are framed (for the time being at least) around universalizing access to drugs and services
rather than the underserved needs of specifically defined racialized groups or populations.7
6 See Mozersky and Gibbon (2014) for an account of how there is a similar questioning of the translation of
risk variables in standardizing BRCA genetic testing for the Brazilian population and also Gibbon (2013).
7 One aspect that deserves emphasis is that over the last decade policies have been implemented especially for
ethnic minorities, such as the “National Policy for Indigenous Health Care” of 2004, and the “National
Policy for Health Care of the Black Population” of 2007. These policies do not relate specifically to the field
of pharmacogenomics. In Brazil, pharmaceutical assistance is part of the national health system (Oliveira et
al, 2007; Petryna, 2009, pp. 146–153). In recent years, several authors have discussed how the premise of
universal access to health within the SUS system has led to a process known as judicialization of the right to
health as patient litigants sue the government so that they can receive treatment (Pepe et al, 2010; Biehl and
Petryna, 2013).
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Placing in Broader Context
Fullwiley (2007) has analyzed how public policy in the United States has molded health
research in such a way that, in order for the research to be funded, racial categories have to
be at the base of methodological designs. It is obligatory, when researchers construct their
samples, to specify a racial group to which a donor belongs, for example: African American,
Native American, Mexican American, Asian, Caucasian orHispanic, even though, as Fullwiley
observes, these classifications are necessarily ambiguous. The author writes that, in 1990, two
government institutions, the US Department of Energy and the National Institutes of Health
(NIH) were major sponsors of the international Human Genome Project. At that time, the
great expectation was that the Project would lead to the development of genetic therapies.
However, according to Fullwiley, current interest in our so-called ‘Genomic Era’ has, in the
United States, turned away from genetic therapy and toward generating knowledge about
specific pharmacogenetic characteristics, based on the genetic profiles of samples whose
ethno-racial classification is a central parameter.
Fullwiley (2007) does not attribute this new perspective to a deliberate ‘racist posture’ on
the part of American government institutions, such as NIH, involved in health research.
According to her analysis, the change is the result of the growing influence of social
movements that have organized politically to gain recognition (see Epstein, 2007). The author
does not question the legitimacy of the scientists’ interest in human variation, but she deplores
the ambiguous way in which racial categories have entered the formulation and analysis of
research in pharmacogenetics. The way in which racial taxa are filled in at the time the
samples are set up is extremely fluid. The researchers may use classifications that they create
themselves, in which case the scientists, observing the appearance (phenotype) of the patient,
place him or her in one of the assigned racial groups, or they may rely on the self-attribution of
the patient, or choose an attribution based on ancestry, or, finally, they may mix various
criteria in setting up a single sample.
Fullwiley shows how, in pharmacogenomic research, differences in appearance that pre-
viously were referred to as race are replaced by certain genes, in a process that she calls the
“molecularization of race”. Through this process, race is assigned by means of “a substance
discernible at the molecular level” (Fullwiley, 2007, p. 4). She observes that the scientists
she interviewed at two major genomic research laboratories in California were preoccupied
with obtaining ‘racially pure’ DNA samples, meaning that for certain research projects
samples from donors with a history of ‘racial mixture’ in the past three generations are
excluded. The author also shows that ‘White’ and ‘Black’ are considered ‘opposites’, so that
it is expected that a high frequency of a gene among White individuals will correspond to a
low frequency of the same gene among Black individuals. When this expectation is not
fulfilled, the explanation is that the persons recruited as donors were not sufficiently ‘pure’
in racial terms.
Another work that is relevant to understanding how the idea of race made its way to
the center of pharmacogenomic studies is one that Bliss (2011, 2012) has written on what
she calls the “genomic elite”, that is, leading researchers at major research institutions in the
field. The author gives the term “reflexive biosociality” to the fact that these researchers,
while at the same time considering race a “social construct”, base their scientific activity on
racial criteria – not to give support to a “racist racial biomedicine” (ibid., p. 1024) – but to
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construct an antidote to racial discrimination. According to her, “these researchers feel that
subject self-identification is enacted in the interest of antiracist values filtered through the
constraints of genomic protocols” (ibid.). Bliss’s approach differs from that of Fullwiley in
terms of the extent to which the use of ‘racial taxonomy’ seems to be problematic for the
scientists she interviewed.
Therefore, while Fullwiley encounters scientists who, while committed to addressing
health disparities and injustices in their work, seem to be somewhat less critical about the
use of racial terminology to qualify their samples, Bliss (2011, 2012) claims that her
interviewees are engaged, and that is the explicit reason why they adopt ‘race’ as a scientific
parameter. Like some of the researchers Fullwiley encounters, they are scientists who, at
some moment in their lives were sensitized against racism, either because they descended
from specific ethnic groups, or recognize that they belong to one of them, or because of
some marked event in their life history. Thus their views, which oppose the idea of ‘race’ as
a substance or type with an insoluble group of defining characteristics, may be compatible
with the intention, through scientific research, of giving visibility to discriminated segments
of society, or of creating conditions for their inclusion. The investigators feel that genomics
can take a central role in this, and “make exceptions for use of racial taxonomy as a
heuristic in research that covers health disparities” (Bliss, 2011, p. 1024). Like Fullwiley,
Bliss points out the importance of the idea of ‘racial purity’ in research, as well as the
ambiguity in the construction of samples that mix alternative criteria, that is genealogy,
self-attribution and classification by the researchers.
Michael Montoya’s work has been more explicitly concerned with question of admixture in
Latin America in the context of genomic research of Type 2 Diabetes among Mexican–
Americans (2007, 2011). He points out how racial purity becomes displaced by concerns
about the need for ‘homogeneity’ in Mexican–American population samples, even as this
also entails a certain naturalization of the social order that reflects somewhat entrenched
patterns of inequality and subjugation. Nevertheless, like Bliss, he encounters scientists
who are reflexively and politically aware of the importance of the ethnoracial taxonomies
in the context of their research. He notes in fact the ways that ethnic identities [and
histories] are pressed “into the service of the biological” in research and development of
the genetic science and medicine in this context. This is a process he terms “bioethnic
conscription” that frequently involves, he points out, a slippage between a simple
pragmatic description of ethnic-racial labels to identify groups to one of the attribution of
qualities to those groups (Montoya, 2007, p. 95). For Montoya, such practices reflect and
inform the “infrastructure of racialization” (Lee, 2005, 2012) in the United States that is
increasingly being incorporated into transnational research.
How does our case study on Brazil fit in these theoretical and ethnographic contexts
we outlined in this article? On the one hand, we suggest that, far from witnessing a
‘molecularization of race’ or admixture as Fuwilley and Montoya outline, the Brazilian
research leads to questioning the validity, for Brazilian (‘racial’) reality, of the parameters
constructing this ‘infrastructure’. This is because the Brazilian research in pharmacogenomics
analyzed in this article tends to work toward the ‘demolecularization of race’, which is
justified by the narrative that places miscegenation as the distinctive and central element in the
biological formation of the Brazilian population. Thus, if ‘races’, as discrete units, are seen
as an “organizing principle … as a natural choice and referent for categorizing humans for
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many working in this field [of pharmacogenomics]” (Fullwiley, 2007, p. 4) in the United
States, in the Brazilian case what is foregrounded is the non-relevance of and an implicit
critique of race as heuristic device in pharmacogenomics research.8
Yet, at the same time, it must be acknowledged that the effort of ‘demolecularizing race’ by
pharmacogenomics in Brazil passes through a process in which, using Lee’s (2005)
term (p. 2134), “bodies and bodily materials are nonetheless racialized institutionally”,
even though this relates in Brazil less to the development of niche markets for new
pharmacogenomic targets than the context in which transnational research, collaboration
and publication take place. We can perceive in the work of Suarez-Kurtz and his collaborators
the use of a heuristic strategy where it is clear that, even while there is a critique of the use of
racial categories in genetic research, there is necessary use value and incorporation of
categories and taxonomies that are somewhat race like; we call this ‘racialize to deracialize’.
This is particularly evident in the investigation on the algorithm for warfarin dosage. In the
case of this study, the investigators started with the presupposition that a ‘racialized’
classification of the subjects, with the categories ‘White’, ‘Intermediate’, and ‘Black’,
would be used as an explanatory variable in the algorithms defining dosage, but later
concluded that this categorization was not a relevant variable. If, in general, investigations to
define algorithms aim to precisely identify and quantify the participation of the so-called
‘independent variables’ (like age, sex, weight, clinical characteristics and so on) in the
expression of the outcome (in this case the dose of warfarin), the strategy followed in the
work of Perini et al (2008) is to point out the unimportance of ‘race’ membership as
an explanatory variable. Thus we have the ‘molecularization of race’, followed by its
‘demolecularization’.9
There are some important parallels in this conclusion with the work of Fujimura and
Rajagopalan examining the use of a particular software for calculating continental ancestry in
the context of Genome Wide Association Studies in the United States. They suggest that
such techniques, that simultaneously produce “different kind of populations” and “popula-
tion differences”, entail what they describe as “genome geography”. Outlining this further
they state:
The concept of genetic ancestry and the practice of genome geography rely on old
discourses, but they also incorporate new technologies, infrastructures, and political
8 As exemplified by Hinterberger’s work in Canada and M’charek’s work in the Netherlands (Hinterberger,
2012; M’charek, 2013), respectively, there has been a growing interest in examining the multiple
manifestations of ‘race’ in genome sciences in different national contexts, thus shedding light on how
different historical and socio-political contexts might influence the incorporation and rejection of race.
Along with our Brazilian case study, this recent body of research enriches the spectrum of critiques in this
area which have been, until recently, to a large extent based on US perspectives on race and science.
9 Following a presentation of this article in a colloquium at the Max Planck Institute for the History of
Science, in Berlin, Veronika Lipphard made an insightful comment that link some of the ideas we discuss
here to key events in the history of physical anthropology. For her, the “racialize to deracialize” approach of
the Brazilian pharmacogeneticists is echoed in Franz Boas’ research in the 1910s on the changing body forms
of descendants of immigrants to the United States. Boas (1912) used long-established anthropometric
techniques to show that facial and cranial characteristics (dolichocephaly, brachicephaly and so on) of the
descendants born in the United States could be different from their parents. Thus, Boas deployed classical
physical anthropology procedures to undermine notions of racial fixity that, to a large extent, were built by
physical anthropologists in the second half of the nineteenth century (see also Stocking, 1974).
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and scientific commitments. Some of these new technologies provide opportunities to
change some of our institutional and cultural forms and frames around notions of
difference and similarity. Nevertheless, we also highlight the slipperiness of genome
geography and the tenacity of race and race concepts
(Fujimura and Rajagopalan, 2011, p. 5).
Similarly even though the Brazilian geneticists situate themselves in terms of a radical rejection
of the use of categories of color and race in the calculation of dosing algorithm for wafarin, it
is important to consider how the work of ‘racializing to de-racialize’ is accomplished using
techniques to characterize human genetic diversity that involve what might appear to be,
stable categories of continental ancestries or race.10
The tension that we suggest is central to the practice of racializing to de-racialize around
incorporation, and rejection of categories of race or continental ancestry in pharmacogenomic
research is nowhere more apparent than in the context of transnational research that the
Brazilian geneticists are engaged with and what might be described as the political economy
surrounding the publication of research.
Considering the circuitous route traveled by scientific data after its production in the
pharmacogenomic laboratories in Brazil, Suarez-Kurtz commented more than once in the
interviews he gave us about his participation in international research consortiums
(that is, multi-centric studies) on the pharmacogenomics of warfarin. These studies involve
comparative analyses of hundreds or thousands of samples from various countries.
An example is the case of the paper, “Estimation of the warfarin dose with clinical and
pharmacogenetic data”, published in the New England Journal of Medicine by the
IWPC (International Warfarin Pharmacogenetics Consortium) et al (2009) and com-
posed by more than a hundred authors.11 The study involved the use of clinical and
genetic data from 4043 patients, with the intent of developing and testing an algorithm
for estimating the appropriate warfarin dose. Suarez-Kurtz said, in our interview, that
only a small portions of the Brazilian samples sent were utilized in the multi-centric study,
and most of the data from individuals classified as ‘Intermediate’ were not included. In fact, in
the article the data that are analyzed are those referred to as ‘White’, ‘Asian’ or ‘Black’,
whereas ‘Mixed or missing data’ constitute a combined category not used in the analyses
(ibid.).
That is, when they enter the ‘political economy’ of publications in pharmacogenomics that
involve extensive international collaboration, often the Brazilian samples, especially those of
‘mestizos’, are not included because they seem not to fit the required ‘racial framework’. The
scientists that Montoya worked with on the genetics of Type 2 Diabetes also confronted
a parallel yet different political economy of publications in their efforts to make their
data publishable and of universal relevance without being ghettoized as being only relevant
10 Although there is a sizable literature on the clinical and genetic aspects of warfarin dosing, including the
proposition of algorithms, we are not aware of any study that has investigated from a social science
perspective the actual practices of warfarin dosing by medical personal in hospitals and other health
provisioning contexts. Anthropological–ethnographic research could potentially illuminate how, in practice,
health professionals perceive and use the dosing algorithms.
11 The examples of warfarin dosing algorithms we have discussed so far reinforce the perspective of genotype-
guided dosing of warfarin. It should be mentioned, however, that there are recent publications that argue
that genotyping does not improve clinical procedures (see, for instance, Kimmel et al, 2013).
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to Mexican–Americans (2007, 2011). Along these lines, if in the perspective of Brazilian
pharmacogeneticists the data produced in the country may serve to produce a critique of the
universalization of data derived from specific contexts (as is the case of warfarin algorithms
developed in the United States), what the example of the multi-centric research seems to
indicate is that many Brazilian samples are not sufficiently ‘racially defined’ to enter the body
of production of a universal and transnational science.
Final Considerations
In a talk he gave at a seminar on pharmacogenomics held in Puerto Rico in 2010 (with the title
“Pharmacogenomic implications of genetic admixture in Brazilians”), one of the many given
on his research at international forums in recent years, Suarez-Kurtz reiterated the conclusion
that he has often repeated in his publications: “The heterogeneity of the Brazilian population
must be taken into account in the design and interpretation of PGx (pharmacogenomic) clinical
trials…” This time Suarez-Kurtz illustrated his remarks with three groups of images. The first,
(surprisingly) along with a quotation on Brazil by the French count Arthur Gobineau (a leading
opponents of miscegenation in the nineteenth century), showed the painting “The Workmen”
(1933) (Os Operários), by Tarsila do Amaral. This work, by one of the most famous Brazilian
modernist painters, depicts the themes of miscegenation (from a positive perspective),
industrialization and social transformation in Brazil (and especially in São Paulo) in the early
decades of the twentieth century.12 The second group of images was, in a way, a re-reading of
Amaral’s work. It presented 14 faces, with the most varied skin color, of personalities who are
famous nowadays in Brazil in the fields of music, sport, literature, architecture, cinema and
medicine. The third group was composed of two photographs of football players (one from
1970 and one from 2006) that may be interpreted as referring to Suarez-Kurtz’s approach to
pharmacogenomics by contrasting models based on discrete racial categories with those that
emphasize the notion of a continuum. In the 1970 photograph, we see two players with distinct
skin color, one Black and one White: one Brazilian (Pelé) and one English (Bobby Moore),
shaking hands at the end of the 1970 World Cup. In the 2006 photograph, five players form a
spectrum from the whitest on the left to the blackest on the right. Bringing together these
groups of images is a quotation from Del Amor y Otros Demonios (Of Love and Other
Demons), a book by the Colombian Nobel Prize Winner Gabriel Garcia Marquez: “At my age
and with so much mixed blood, I no longer know for sure where I belong. Nobody knows it in
these lands… and I believe that it will take centuries to know it”.
Thus Suarez-Kurtz builds his arguments through a conjunction of ideas about the history of
the country, ‘mixed blood’, science and nation building, which are articulated with recent
knowledge from the field of pharmacogenomics. In the term of Sommer (2010), we may say that
Suarez-Kurtz recounts a ‘biohistory’ of the Brazilian genome, which in his perspective is seen as
patrimony and ‘archive of history’ that must be taken in consideration when setting the priorities
for research on the interface of human biological diversity and pharmacology. Such narratives
12 It is perhaps important to note also the parallels between the movement of ‘anthropophagy’ that Tarsila do
Amaral was part of in the early part of the twentieth century and that sought (in a similar way to the Brazilian
geneticists described in this article) to incorporate and reject European painting and artistic styles and forms
(Gonçalves, 2012). In this sense the choice of images by the Brazilian pharmacogeneticists is telling.
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have been extensively analyzed in the literature of anthropology, sociology and that of STS
scholars, stretch outward from the individual level, passing through social groups, to reach
the level of nations (see, for instance, Rabinow, 2002; Hinterberger, 2012). When Suarez-Kurtz
says “It is most likely that this [Brazilian pharmacogenomic profile] applies to other admixed
populations of the Americas”, he takes the Brazilian context as representative of a “Latin
American imagined (pharmaco)genetic community”, (see Simpson, 2000) where the question of
‘mixed race’ would be regarded in a fundamentally different way than in regimes where the
production of pharmacogenomic knowledge is based on membership in discrete ethno-racial
groups. Hence, Suarez-Kurtz, in his own words, suggests that scientific knowledge should not
lose sight of its roots when immersed in the complex and controversial realities of particular
historical situations. In this sense, the significance of the pharmacogenomic research in Brazil is
that it presents, at least in part, some elements of a counter discourse as it both makes use of and
simultaneously challenges the globalization of (pharmaco)genes, bodies, ethno-racial categories
and technology derived from particular contexts.13
Nevertheless, at the same time that the perspective espoused by Suarez-Kurtz on the matter
of race and the pharmacogenomics of warfarin is far removed from some major lines of
reasoning on the topic in the United States, there is some comparability in the way that its
central message makes use of an emphasis on the individual. Thus, at the same time that the
perspective of the Brazilian geneticists presents marked differences from the ones prevailing in
the United States, it also paradoxically parallels some aspects, as it rests on and draws its force
from recognizing the need for individualized treatments. The fact that this very prominent
American discourse, that has been central to the pursuit of personalized medicine within
pharmacogenomics, is also highlighted in the Brazilian context provides further evidence
of how there is an ‘incorporation’ and not simply or only a rejection of specific aspects of
US–European pharmacogenetic research.
Throughout this article, we have tried to show that pharmacogenomics in Brazil must
be understood as scientific practice deeply embedded in the values and history of the society
where it is produced. In this sense, there are significant differences but also similarities with
arguments recently put forward by scholars who have analyzed the interface between ethno-
racial categories and pharmacogenomics. If one of Fullwiley’s (2007) aims is to understand
“how do scientists today use race as a biogenetic entity” (p. 2), our aim in this work has been
not to understand race is ‘used’ as a biogenetic entity, but how do [Brazilian] scientists today
simultaneously incorporate and reject race as a biogenetic entity. In the same way that Bliss
(2011) points out that the scientists she interviewed “practice a reflexive form of biosociality
in which they actively work to refashion ideas based on the kind of biosocial future they want
for society” (p. 8), from the pharmacogenomic algorithms presented by Suarez-Kurtz a
biosociality emerges that is deeply embedded in a positive discourse about miscegenation. In
terms of health, the ‘biosocial future’ that pharmacogenomics pictures for Brazil is one where
the biological characteristics of individuals, and not those of ‘race’, should be emphasized in
the routines of drug administration, even as the individuality at stake must be read through
13 In this article, which addresses the particular case of warfarin, we are not implying that in other areas of
genetic research human geneticists, pharmacologists and other scientists in the United States do not take into
account the issue of admixture. Even a brief search in broadly used bibliographic databases, like PubMed-
line, show that admixture is an important topic of research in human genetics in the United States. However,
this does not seem to be the case in the literature on warfarin dosing algorithms.
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the increasingly ubiquitous promise of personal medicine and highly particular histories and
politics of race, color and national identity.
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